A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
Verywell Health on MSN2d
Another Study Links Ozempic to a Rare Eye Condition That Can Cause Vision LossA new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...
Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...
Seeking Alpha on MSN1d
Novo Nordisk seeks to block compounded VictozaNovo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
A Scandinavcian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many ...
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback